Back to mobile site

OptimizeRX (OPRX) Reiterated at Buy by Stifel as New AI Tool Launched

June 29, 2026 7:24 AM EDT Send to a Friend
Stifel analyst David Grossman reiterated a Buy rating and $14.00 price target on OptimizeRX (NASDAQ: OPRX).The analyst commented, "This week ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login